Literature DB >> 24000249

Unclassified or unclassifiable interstitial lung disease: confusing or helpful disease category?

Vincent Cottin, Athol Wells.   

Abstract

Entities:  

Mesh：

Year:  2013        PMID： 24000249     DOI： 10.1183/09031936.00107713

Source DB:  PubMed          Journal:  Eur Respir J        ISSN： 0903-1936            Impact factor:   16.671


× No keyword cloud information.
  4 in total

1.  A Standardized Diagnostic Ontology for Fibrotic Interstitial Lung Disease. An International Working Group Perspective.

Authors:  Christopher J Ryerson; Tamera J Corte; Joyce S Lee; Luca Richeldi; Simon L F Walsh; Jeffrey L Myers; Jürgen Behr; Vincent Cottin; Sonye K Danoff; Kevin R Flaherty; David J Lederer; David A Lynch; Fernando J Martinez; Ganesh Raghu; William D Travis; Zarir Udwadia; Athol U Wells; Harold R Collard
Journal:  Am J Respir Crit Care Med       Date:  2017-11-15       Impact factor: 21.405

2.  Efficacy of Pirfenidone vs. Placebo in Unclassifiable Interstitial Lung Disease, by Surgical Lung Biopsy Status: Data From a post-hoc Analysis.

Authors:  Maria Molina-Molina; Michael Kreuter; Vincent Cottin; Tamera J Corte; Frank Gilberg; Klaus-Uwe Kirchgaessler; Judit Axmann; Toby M Maher
Journal:  Front Med (Lausanne)       Date:  2022-06-17

3.  Pirfenidone in patients with unclassifiable progressive fibrosing interstitial lung disease: design of a double-blind, randomised, placebo-controlled phase II trial.

Authors:  Toby M Maher; Tamera J Corte; Aryeh Fischer; Michael Kreuter; David J Lederer; Maria Molina-Molina; Judit Axmann; Klaus-Uwe Kirchgaessler; Vincent Cottin
Journal:  BMJ Open Respir Res       Date:  2018-09-04

Review 4.  A contemporary practical approach to the multidisciplinary management of unclassifiable interstitial lung disease.

Authors:  Christopher J Ryerson; Tamera J Corte; Jeffrey L Myers; Simon L F Walsh; Sabina A Guler
Journal:  Eur Respir J       Date:  2021-12-16       Impact factor: 16.671
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.